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LETTERS TO THE EDITORCONSENSUS PANEL OPINION
FOR MINIMALLY INVASIVE
AORTIC VALVE
REPLACEMENT: ASSESSING
POTENTIAL CONFLICT OF
INTEREST
To the JTCVS Readers:
In the January 2014 issue of The
Journal of Thoracic and Cardiovascu-
lar Surgery, Malaisrie and associates1
published a consensus panel opinion
document describing the intraopera-
tive steps as well as key preoperative
evaluation and planning and postoper-
ative considerations for minimally
invasive aortic valve replacement
(MIAVR). Their recommendations
were based on the combined experi-
ence of nearly 5000 MIAVRs per-
formed by 20 surgeons at 19
institutions. Of the 20 surgeons, 19 re-
ported consulting and/or lecture fees
from Edwards; 6 from Medtronic; 4
from Atricure; 3 from St. Jude; and 1
each from Estech, Cardionet,
Abiomed, Sorin, Mitralign, Abbott,
LSI, Terumo, and Intuitive Surgical.
The author list also included 2 full-
time employees of Edwards Life-
sciences. All of these disclosures
were clearly outlined on the first
page of the manuscript, both in the
printed journal and online. In addition,
it is important to clarify that this
manuscript went through an appro-
priate, thorough review by the Editor,
Associate Editor, and independent re-
viewers who expressed no conflict of
interest in regards to the content they
evaluated.The Editor welcomes submissions for possible publica-
tion in the Letters to the Editor section that consist
of commentary on an article published in the Journal
or other relevant issues. Authors should:  Include
no more than 500 words of text, three authors,
and five references.  Type with double-spacing.
 See http://jtcs.ctsnetjournals.org/misc/ifora.shtml
for detailed submission instructions.  Submit the
letter electronically via jtcvs.editorialmanager.com.
Letters commenting on an article published in the
JTCVS will be considered if they are received
within 6 weeks of the time the article was published.
Authors of the article being commented on will be
given an opportunity of offer a timely response
(2 weeks) to the letter. Authors of letters will be
notified that the letter has been received.Unpublished
letters cannot be returned.
The JournalWe found the text of this manu-
script to be timely, very well-written,
and beautifully illustrated. It should
serve as an outstanding resource for
surgeons interested in developing an
MIAVR program. That being said,
we feel it is important to clarify a po-
tential conflict of interest that appears
in this manuscript in regards to the
specific equipment recommendations
that exist in Appendix 1. Appendix 1
is a list of ‘‘author recommended
products’’ organized into 14 distinct
categories for MIAVR, and it is refer-
enced throughout the manuscript. No-
where, however, is there a clear
description of how this product list
was generated.
It is essential to point out that there
are many alternatives available in the
majority of these categories that are
not included in the product list gener-
ated by the panel, and in many cases,
the best option may not be included.
In addition, some of the information
presented is incomplete. One example
occurs on page 9 of the text when the
authors appropriately note that,
‘‘Smaller aortic cannulae are
preferred (Appendix 1, 2).’’ Category
2 of the appendix then lists 2 aortic
cannula options: The first (OptiSite
from Edwards) is identified in size
18, 20, and 22 Fr, whereas the second
(Sarns Soft-Flow from Terumo) is
identified in size 21 and 24 Fr. The
less experienced reader may then as-
sume that the first choice is, therefore,
best because it offers the smallest size.
Unfortunately, the authors failed to
mention that the Sarns Soft-Flow is
also available in size 18 Fr; Terumo
makes a high-flow aortic arch cannula
down to size 12 Fr; and Medtronic,
which was not included as an option,
produces pediatric aortic cannulae
down to size 6 Fr. These are the types
of omissions that well-intending sur-
geons can make when trying to select
products to recommend with which
they may have a conflict of interest.
Other omissions include the Carpent-
ier Bi-Caval Femoral Venous Cannula
from Medtronic, STAR soft tissueof Thoracic and Cardiovascular Surgerretractor from Estech, Chitwood De-
Bakey low-profile aortic clamp from
Scanlon, and a myriad of chest drains
to name but a few. It is also unclear
how the order in which products
were listed within a certain category
was determined. It was not alphabet-
ical by product; alphabetical by manu-
facturer; nor based on market share,
panel vote, or a subjective measure
of quality. In many categories, howev-
er, it does not appear random.
In summary, we feel that it is essen-
tial to reinforce to readers of the Jour-
nal that this appendix does not
represent a complete list of available
options to perform MIAVR nor does
it necessarily include even the most
appropriate option for each category.
The authors are to be commended
for including full disclosure of poten-
tial conflict of interest in the manu-
script, but we all need to realize that
it is virtually impossible for a person
with a conflict of interest to recom-
mend products in an unbiased fashion,
no matter how hard they try.
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HEALTHY YOUNG WOMAN
To the Editor:
Inflammatory myofibroblastic tu-
mor is a relatively rare neoplasm of
unknown etiology. It occurs at variousy c Volume 147, Number 3 1109
FIGURE 1. Preoperative echocardiography. RV, Right ventricle; LV, left ventricle; T, tumor
(located in the left ventricular outflow tract); Ao, aorta; LA, left atrium.
Letters to the Editorsites but is usually located in the
lungs. By definition, it is composed
of spindle cells (myofibroblasts) with
variable inflammatory components.
Extrapulmonary forms are rare and
are more common in adult female
patients.1 The patients often are seen
with fever of unknown origin and
other vague, nonspecific symptoms.
Inflammatory myofibroblastic tumor
occurs extremely rarely in the heart.
A study by Burke and colleagues2
demonstrated that the lesions may be
located in the right atrium, rightFIGURE 2. Gross appeara
1110 The Journal of Thoracic andventricular inflow tract, right ventri-
cular outflow tract, mitral valve, aortic
valve, left coronary sinus, or left
ventricular free wall. Inflammatory
myofibroblastic tumor is potentially
dangerous. There have been cases
described in which myocardial
ischemia related to a tumor in the
coronary artery resulted in sudden
death.2,3
We report the case of a female
patient, a student 21 years of age
without relevant previous medical
history, who was admitted to thence of resected tumor.
Cardiovascular Surgery c March 2014clinic after an incidental diagnosis
of heart tumor. The patient had
been seen with a 3-week history of
symptoms of chest pain, fast heart
beating, dizziness, and loss of
consciousness. There were no signi-
ficant changes in laboratory results,
chest radiography, or electrocardio-
graphy. Under transthoracic echocar-
diographic examination, the tumor
appeared as a mobile mass with a
diameter of 1.5 to 2 cm, causing a
gradient of 39.3 mm Hg in the left
ventricular outflow tract (Figure 1).
The aortic valve was found to be
compliant, without any signs of
insufficiency. Surgery was performed
the day after the diagnosis was made,
and the tumor was successfully re-
sected (Figure 2). There were no
complications in the postoperative
period. Three years after the opera-
tion, the patient is free of symptoms,
and there have been no new findings
or tumor recurrence on echocardio-
graphic examination.
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